

Cover Story
By Matthew Bin Han Ong
NCI is opening up its contract for operations and technical support at the Frederick National Laboratory for Cancer Research for re-competition—a process that officials said will take up to two years.
By Nick Crispino
In Brief


Drugs & Targets
Trending Stories
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA











